The Short Answer
When people search "peptides for weight loss," they usually mean one of two things: the GLP-1 class of prescription drugs (semaglutide, tirzepatide, and newer pills) or the gray-market research peptides sold online for fat loss (AOD-9604, MOTS-c, "retatrutide" vials).
Only the first group has proof. Semaglutide and tirzepatide each have multi-thousand-person controlled trials, FDA labels, and years of real-world use. The research peptides have animal data, small studies, or nothing. Retatrutide sits in between: strong Phase 2 and Phase 3 trial results, but no approval yet and no legal supply.
This hub explains how GLP-1 drugs work, what each one showed in trials, where the investigational options stand, and how to get evaluated by a licensed clinician. It does not recommend doses. Dosing for approved drugs comes from the label and the prescriber.
How GLP-1 Peptides Cause Weight Loss
GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. Natural GLP-1 lasts only minutes. The drugs are engineered versions that bind the same receptor but last about a week.
When a GLP-1 receptor agonist is active:
- Appetite drops. The brain's satiety signaling increases; many people describe less "food noise." See GLP-1 and food noise.
- The stomach empties more slowly, so meals feel filling for longer.
- Insulin response after meals improves and glucagon falls, which is why the class started as diabetes treatment.
Tirzepatide adds a second hormone receptor, GIP, and retatrutide adds a third, glucagon, which is thought to raise energy expenditure. More receptors have produced more weight loss in trials, along with the same core side-effect profile. Mechanisms in detail: semaglutide vs tirzepatide vs retatrutide.
The Approved Weight-Loss Peptides
| Drug | Receptors | Approved for weight management | Key trial result |
|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 | June 2021 (injection); Dec 2025 (oral tablet) | STEP 1: 14.9% mean weight loss at 68 weeks vs 2.4% on placebo |
| Tirzepatide (Zepbound) | GIP + GLP-1 | Nov 2023 | SURMOUNT-1: 15.0%, 19.5% and 20.9% at 72 weeks (5, 10 and 15 mg) vs 3.1% on placebo |
| Orforglipron (Foundayo) | GLP-1 (oral small molecule, not a peptide) | April 2026 | Once-daily pill; see our Foundayo guide |
Semaglutide
Wegovy's label covers chronic weight management in adults with obesity, or overweight with at least one weight-related condition, and in adolescents 12 and older with obesity. It also carries an indication to reduce major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. In the STEP 1 trial, 86% of participants on semaglutide lost at least 5% of body weight and half lost at least 15%. Guide: semaglutide for weight loss.
Tirzepatide
Zepbound's label covers weight management and, since late 2024, moderate to severe obstructive sleep apnea in adults with obesity. In SURMOUNT-1, more than half of participants on the two higher doses lost 20% or more of their body weight. The most common side effects were gastrointestinal, mostly mild to moderate, and concentrated during the dose-escalation period. Guide: what is tirzepatide.
Oral options
Two pills now exist for weight management. The oral semaglutide tablet (Wegovy) was approved in December 2025, and orforglipron (Foundayo) in April 2026. Orforglipron is not a peptide; it's a small molecule that activates the GLP-1 receptor, which is what lets it survive digestion. Rybelsus, the older oral semaglutide, is approved for type 2 diabetes, not weight management.
Retatrutide: Investigational, Not Available
Retatrutide is Eli Lilly's triple agonist (GIP, GLP-1 and glucagon). In the Phase 2 trial, the 12 mg group lost a mean of 24.2% of body weight at 48 weeks. Phase 3 TRIUMPH trials reported in 2026. Lilly plans to file for approval in the first quarter of 2027.
Three things to know before searching for it:
- It isn't approved anywhere, so there is no legal prescription supply.
- FDA has said it cannot be used in compounding under federal law.
- Vials sold online are unverified. Lilly has sued sellers, FDA has sent warning letters, and lab tests have found "retatrutide" that contained a different drug.
Everything we've published on it, including trial-reported dose data, is in the retatrutide guide and hub.
Research Peptides Marketed for Fat Loss
These show up in "best peptides for weight loss" lists. None has the evidence of a GLP-1 drug:
- AOD-9604: a fragment of growth hormone studied for fat metabolism. Not approved; only small human studies, none supporting it as a weight-loss treatment. AOD-9604 guide.
- MOTS-c: a mitochondrial peptide with rodent exercise and metabolism data and very early human work. Not approved. MOTS-c guide.
- 5-Amino-1MQ: a small molecule, not a peptide, studied in cells and mice.
- Tesamorelin: approved only for excess abdominal fat in HIV-associated lipodystrophy, not general weight loss. What tesamorelin does.
If a seller promises GLP-1-level results from any of these, the evidence doesn't support it.
Compounded GLP-1s: What FDA Says
Compounded semaglutide and tirzepatide became common during the drug shortages. FDA's consumer guidance on unapproved GLP-1 products warns that compounded versions are not FDA-approved, that some compounders have used salt forms of semaglutide (semaglutide sodium or acetate) that are different active ingredients from the approved drug, and that dosing errors have been reported with vial-and-syringe products. FDA also lists telehealth red flags: claims that a compounded drug is "the same" as the approved one, deep discounts, and products that look different from what a pharmacy dispenses.
